BeStock  
Stocks › Biotechnology › CRVS

Corvus Pharmaceuticals CRVS

US equityMarket cap rank #3290Biotechnology
$9.67 −$0.34 (-3.40%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.67 0.00%
Open$9.84
Prev close$10.01
Day range$9.56 – $10.04
Volume927.5K
Market cap$815.69M
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership86.0%-2.06 pts vs. prior quarter
Institutions holding207-1 vs. prior quarter
Insider trades (recent)47 buys / 2 sellsNet buying
Short interest21.11% of floatDays to cover 18.9 · as of 30 Oct 2026
Short-sale volume share23.4%5-day average of daily volume

Short-sale volume as % of daily volume

13%20%28%36%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$171.5K (9 inflow days, 11 outflow days).

Net flow by order size, last 20 sessions

−$267.4KSuper+$95.9KBig+$226.3KMid+$923.6KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 29.3% of shares outstanding.

Largest holders

  • OrbiMed Advisors LLC8.49%
  • BlackRock8.42%
  • T. Rowe Price Group, Inc.4.49%
  • State Street Global Advisors3.95%
  • Vanguard Capital Management, LLC3.93%
  • Adams Street Partners, LLC3.88%
  • Vivo Capital, LLC3.33%
  • Wellington Management Group3.24%

By investor type

  • Mutual Fund41.00%
  • VC/PE Fund27.06%
  • Hedge Fund11.23%
  • Public Company4.22%
  • Individual/Insider3.53%
  • Private Company1.78%
  • Insurance Company0.39%
  • Government Pension Fund0.25%

Reported short interest has fallen from 22.74% to 21.11% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Fisher Investments Mutual Fund 2026/Q3 +1,040,606 1.2%
Connor, Clark & Lunn Investment Management Ltd. Mutual Fund 2026/Q3 +205,512 0.5%
SEI Investments Company Mutual Fund 2026/Q3 +101,509 0.2%
Squarepoint OPS LLC Hedge Fund 2026/Q3 +85,818 0.2%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +152,628 0.2%
BlackRock Mutual Fund 2026/Q3 +978,389 8.5%
State Street Global Advisors Mutual Fund 2026/Q3 +908,099 5.3%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q3 +871,826 4.5%
Eversept Partners, L.P. Hedge Fund 2026/Q3 +747,994 0.9%
Bank of America Corporation Public Company 2026/Q3 +520,794 0.9%
Wellington Management Group Mutual Fund 2026/Q3 +413,115 3.2%
Perceptive Advisors LLC VC/PE Fund 2026/Q3 +375,000 3.2%
Braidwell LP Hedge Fund 2026/Q3 +373,500 2.5%
Trexquant Investment LP Hedge Fund 2026/Q3 +296,347 0.4%
Two Sigma Investments, LP Hedge Fund 2026/Q3 +245,339 0.9%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
12 Nov 2026 Jeffrey Arcara Senior VP & Chief Business Officer Open Market Acquisition +4,500 $11.46 4,500
10 Jun 2026 Richard van den Broek Independent Director Other Derivative Acquisition +15,000 $11.60 15,000
10 Jun 2026 Linda Grais Independent Director Other Derivative Acquisition +15,000 $11.60 15,000
10 Jun 2026 Ian T. Clark Former Independent Director Other Derivative Acquisition +15,000 $11.60 15,000
10 Jun 2026 Peter Thompson Co-Founder & Independent Director Other Derivative Acquisition +15,000 $11.60 15,000
10 Jun 2026 David Moore Independent Director Open Market Acquisition +21,700 $11.53 21,700
10 Jun 2026 David Moore Independent Director Other Derivative Acquisition +15,000 $11.60 15,000
17 May 2026 Richard Miller Co-Founder, President, CEO & Chairman of the Board Open Market Acquisition +6,932 $12.05 2,331,742
27 Jan 2026 Peter Thompson Co-Founder & Independent Director Derivative Exercise and Retained +210,000 $15.00 210,000
3 Dec 2025 Richard Miller Co-Founder, President, CEO & Chairman of the Board Other Derivative Acquisition +1,000,000 $8.81 1,000,000
3 Dec 2025 Leiv Lea Chief Financial Officer Other Derivative Acquisition +400,000 $8.81 400,000
3 Dec 2025 Jeffrey Arcara Senior VP & Chief Business Officer Other Derivative Acquisition +100,000 $8.81 100,000
3 Dec 2025 William Jones Senior Vice President of Pharmaceutical Development Other Derivative Acquisition +400,000 $8.81 400,000
1 Oct 2025 David Moore Independent Director Other Derivative Acquisition +30,000 $7.04 30,000
26 Jun 2025 OrbiMed Advisors LLC Derivative Exercise and Sale -1,176,332 $4.16 7,165,006
26 Jun 2025 OrbiMed Advisors LLC Derivative Exercise and Retained +221,352 $3.50 7,165,006
11 Jun 2025 Linda Grais Independent Director Other Derivative Acquisition +15,000 $4.24 15,000
11 Jun 2025 Ian T. Clark Former Independent Director Other Derivative Acquisition +15,000 $4.24 15,000
11 Jun 2025 Peter Thompson Co-Founder & Independent Director Other Derivative Acquisition +15,000 $4.24 15,000
11 Jun 2025 Scott William Morrison Former Independent Director Other Derivative Acquisition +15,000 $4.24 15,000

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 17,759,451 21.1% 18.9
15 Oct 2026 17,967,756 21.4% 14.9
30 Sep 2026 17,797,751 21.2% 13.3
15 Sep 2026 17,180,341 20.4% 18.2
31 Aug 2026 19,017,840 22.6% 29.6
14 Aug 2026 19,127,098 22.7% 22.5

Discussion

No comments yet — be the first to weigh in on CRVS.

Sign in to join the discussion.

Scroll to Top